ABBV-547 / AbbVie - LARVOL DELTA

A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections (clinicaltrials.gov) - P1 | N=121 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting

Adverse events • Enrollment closed • First-in-human

A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections (clinicaltrials.gov) - P1 | N=121 | Recruiting | Sponsor: AbbVie | N=87 ➔ 121

Adverse events • Enrollment change • First-in-human

AbbVie Completes Acquisition of Nimble Therapeutics (PRNewswire) - "AbbVie...announced today that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a part of AbbVie. Nimble's lead asset is an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis."

M&A • Psoriasis